Laurence is a highly-experienced European and UK qualified patent attorney with over 25 years’ experience handling pharmaceutical and biotechnology subject matter. He has successfully managed patent portfolios on a variety of biotechnology subject matter, including diagnostic tools and targets, personalised healthcare (PHC), antisense oligonucleotide molecules, peptide and antibody (e.g. polyclonal, monoclonal, bispecific and conjugated) therapeutics, as well as handling the IP for small molecule discovery and high profile on sale pharmaceutical products, some with greater than $1bn annual sales.
After gaining a PhD in molecular biology from Reading University, Laurence joined a small biotechnology company to work in the laboratory on virus-based antigen delivery systems. After a couple of years, he moved internally to train as a patent attorney. In the same year as qualifying as European patent attorney Laurence joined the in-house patent department of AstraZeneca Pharmaceutical Ltd. where he worked for over 18 years before joining HGF’s Manchester office as a Patent Director in September 2017.
Cell and Molecular Biology
Molecular Biology - Reading University
Certificate in Intellectual Property Law - Queen Mary University of London
June 27th 2022
January 14th 2021
October 17th 2019
Medical Technology Ireland Conference 2022 will be held on 21-22 September at the Galway Racecource. Medical Technology Ireland is a new high-profile National and International event attracting global suppliers to …Event details
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.